CORMEDIX INC (CRMD)
Sector: Health Care
2026 Annual Meeting Analysis
CORMEDIX INC · Meeting: June 23, 2026
Directors FOR
7
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Approval of the Director Election Proposal
Director since August 2015 with strong healthcare technology executive experience; CRMD's 3-year price return of +59.8% outpaces the XBI (SPDR S&P Biotech ETF) return of +57.9% by +1.9 percentage points, well within the 65-point threshold required to trigger a vote against, and no overboarding, attendance, or independence concerns were identified.
Director since November 2020 with deep pharmaceutical industry executive experience; TSR performance versus XBI (SPDR S&P Biotech ETF) does not trigger a concern, attendance is adequate, and no overboarding or independence issues were identified, though his concurrent CEO role at Dogwood Therapeutics (DWTX) is noted — he holds one outside public board seat, within the two-seat limit for sitting CEOs.
Director since March 2019 with substantial pharmaceutical R&D experience; CRMD's 3-year return versus XBI (SPDR S&P Biotech ETF) does not trigger the TSR threshold, attendance meets the 75% standard, and while Dr. Dunton serves on three other public company boards (Palatin, Oragenics, Recce Pharma), this totals four public company board seats including CRMD, which is at but not over the four-board limit under the policy.
Lead Independent Director since January 2026 (previously Chairman since August 2017) with deep corporate and securities law experience; TSR performance versus XBI (SPDR S&P Biotech ETF) does not trigger a concern, attendance is adequate, and no overboarding or independence issues were identified.
Director since June 2017 with financial advisory expertise and designated as an audit committee financial expert; CRMD's 3-year return versus XBI (SPDR S&P Biotech ETF) does not trigger the TSR threshold, attendance meets the 75% standard, and no overboarding or independence issues were identified.
CEO and director since March 2022; as an executive director he is subject to the same TSR trigger as all other directors, but CRMD's 3-year price return of +59.8% versus XBI (SPDR S&P Biotech ETF) at +57.9% produces a gap of only +1.9 percentage points, far below the 65-point threshold needed to trigger a vote against, so no TSR concern applies.
Director since April 2023 with extensive pharmaceutical executive experience; his tenure began fewer than 36 months ago and covers less than half the 3-year measurement window, so even if a TSR concern existed the policy calls for only a flag rather than an automatic vote against, and in any event CRMD's TSR gap versus XBI (SPDR S&P Biotech ETF) does not reach the trigger threshold.
All seven nominees pass the policy screens: CRMD's 3-year price return of +59.8% outperforms or closely tracks the XBI (SPDR S&P Biotech ETF) benchmark (+57.9%), producing a gap of just +1.9 percentage points against a 65-point trigger threshold; all directors met the 75% attendance standard; no overboarding violations are confirmed; all independent directors are properly classified; and no familial relationships to senior management were disclosed.
Say on Pay
✓ FORCEO
Joseph Todisco
Total Comp
$6,101,176
Prior Support
N/A
CEO Joseph Todisco received total compensation of approximately $6.1 million in 2025, driven primarily by a large equity award of $4.49 million (restricted stock units and performance stock awards) that represents roughly 74% of his total pay, which is well above the 50-60% variable pay threshold — meaning the pay structure is heavily equity-weighted in a way that favors long-term alignment. The performance stock awards vest based on relative shareholder return over three years, which is a meaningful, objective performance condition tied directly to shareholder outcomes rather than an easily manipulated short-term metric. The company adopted a proper clawback policy in December 2023 and CRMD's 3-year stock return of +59.8% roughly matches the XBI (SPDR S&P Biotech ETF) benchmark return of +57.9%, so the pay-for-performance alignment check does not trigger a concern, and on balance the compensation structure supports a FOR vote.
Auditor Ratification
✓ FORAuditor
CBIZ CPAs P.C.
Tenure
1 yrs
Audit Fees
$1,180,448
Non-Audit Fees
$0
CBIZ CPAs P.C. was engaged in April 2025, giving it roughly one year of tenure, which is well below the 25-year threshold that would raise independence concerns; non-audit fees are zero, so the non-audit fee ratio is 0%, far below the 50% trigger; and CBIZ absorbed the Marcum attest practice and partners who previously audited the company, providing continuity of expertise at a firm appropriate for a company of CRMD's market cap.
Stockholder Proposals
6 proposals submitted by shareholders
Proposal 4
Approval of the Ratification of the COD Amendments Proposal
This is a board-initiated proposal under a Delaware law procedure (Section 204 of the DGCL) to retroactively confirm prior amendments to the preferred stock certificates of designation, which the board believes were validly adopted but where a stockholder raised a technical question about authorization; approving it removes potential legal uncertainty in the capital structure at minimal cost to common stockholders. Critically, the proposal explicitly preserves all existing rights of common stockholders and does not change any terms applicable to common stock. Failing to approve it could expose the company to costly litigation over technical procedural questions, which would harm all shareholders.
Proposal 5
Approval of the Amended Charter Proposal
This proposal makes purely technical and housekeeping changes to the charter — updating the registered agent address, removing references to preferred stock series that no longer exist, deleting references to a 2019 reverse stock split, aligning the indemnification provision with existing bylaws, and adding article titles — none of which change the substantive rights of common stockholders. These are the kind of modernizing clean-up amendments that any well-governed company should undertake periodically, and the proxy makes clear that no substantive rights are affected. Supporting this proposal costs shareholders nothing and results in a cleaner, more readable governing document.
Proposal 6
Approval of the Class Voting Proposal
This proposal clarifies that when a charter amendment relates solely to one series of preferred stock and does not touch common stock terms, only the holders of that preferred series need to vote — which is logically consistent with the principle that people should vote on things that directly affect them. The proposal explicitly states that common stockholders retain full voting rights on any amendment that changes common stock terms, so no common stockholder right is taken away. Avoiding the need to run a full common stockholder vote for purely preferred-stock technical amendments saves meaningful cost and management time, and this approach is consistent with Delaware law and widely used by other public companies.
Proposal 7
Approval of the Exclusive Forum Proposal
Designating the Delaware Court of Chancery and federal district courts as exclusive forums for corporate law claims and Securities Act claims is a mainstream governance practice widely adopted across public companies; it reduces the company's exposure to duplicative lawsuits filed in multiple states simultaneously, which can dramatically increase legal costs that ultimately come out of shareholder value. Delaware courts have deep expertise in corporate law and provide more predictable, consistent outcomes. While exclusive forum clauses technically limit where shareholders can sue, the courts designated are fully capable of fairly adjudicating these claims, and the cost savings benefit all shareholders.
Proposal 8
Approval of the Updating Officer Liability Provisions as Permitted by Delaware Law Proposal
This proposal limits officer liability only for certain duty-of-care claims brought directly by stockholders, and explicitly preserves full liability for breaches of the duty of loyalty, intentional misconduct, bad faith, knowing violations of law, transactions where the officer personally benefited improperly, and any claims brought by the company itself — meaning the most serious forms of misconduct remain fully actionable. Delaware updated its law in 2022 to permit this protection, and many comparable public companies have already adopted it; failing to do so could make it harder to recruit and retain qualified executives. The protection is narrow, balanced, and aligned with the treatment already extended to directors under the existing charter.
Proposal 9
Approval of the Adjournment Proposal
This is a standard procedural proposal that only comes into play if Proposals 4 through 8 do not receive sufficient votes; it simply allows more time to collect proxies rather than letting important proposals fail on a timing technicality. Adjournment proposals tied to specific substantive votes are routine housekeeping measures and there is no governance concern with supporting it.
Overall Assessment
The 2026 CorMedix annual meeting presents a clean ballot with no significant governance red flags: the full seven-director slate passes TSR, attendance, independence, and overboarding screens given that CRMD's 3-year stock return of +59.8% nearly matches the XBI (SPDR S&P Biotech ETF) benchmark of +57.9%; the CEO's $6.1 million pay package is heavily equity-weighted with meaningful performance conditions; and the auditor CBIZ CPAs is new with zero non-audit fees. The four charter amendment proposals (Proposals 5–8) and the COD ratification (Proposal 4) are all board-initiated measures that either clean up outdated language, clarify procedurally sound voting mechanics, reduce litigation costs, or align officer protections with existing director protections, none of which diminish common stockholder rights.